Rezultati pretrage - Alberto D’Angelo

  • Prikaz rezultata 1 – 11 od 11
Detaljiziraj rezultate
  1. 1
    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma

    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma od Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, Giovanni Marchegiani

    Izdano 2025
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  2. 2
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer od Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Tobias Otto

    Izdano 2019
    Preuzmi cijeli tekst
    Pré-impressão
    Spremi u popis
    Spremljeno u:
  3. 3
    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy

    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy od Maria Grazia Rodriquenz, Giandomenico Roviello, Alberto D’Angelo, Daniele Lavacchi, Franco Roviello, Karol Połom

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  4. 4
    Advances in anti-BRAF therapies for lung cancer

    Advances in anti-BRAF therapies for lung cancer od Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  5. 5
    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy od Marianna Sirico, Alberto D’Angelo, Caterina Gianni, Chiara Casadei, Filippo Merloni, Ugo De Giorgi

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  6. 6
    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer od Giandomenico Roviello, Alberto D’Angelo, Roberto Petrioli, Franco Roviello, Fabio Cianchi, Stefania Nobili, Enrico Mini, Daniele Lavacchi

    Izdano 2020
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  7. 7
    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption

    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption od Navid Sobhani, Praveen Neeli, Alberto D’Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  8. 8
    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer od Navid Sobhani, Anna Ianza, Alberto D’Angelo, Giandomenico Roviello, Fabiola Giudici, Marina Bortul, Fabrizio Zanconati, Cristina Bottin, Daniele Generali

    Izdano 2018
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  9. 9
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer od Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Anna Miccoli, Silvia Paola Corona, Ottavia Bernocchi, Daniele Generali, Tobias Otto

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  10. 10
    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use

    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use od Tomasz Cwalinski, Wojciech Połom, Luigi Marano, Giandomenico Roviello, Alberto D’Angelo, Natalia Cwalina, Marcin Matuszewski, Giandomenico Roviello, Janusz Jaśkiewicz, Karol Połom

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  11. 11
    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies od Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:

Alati za pretragu: